Samsung BioLogics says report on Biogen deal talks untrue.

Samsung BioLogics says report on Biogen deal talks untrue.
Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S.
drugmaker Biogen Inc.
Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion.
Biogen is valued at $34.67 billion, according to Refinitiv data.
To stay up to date with latest top stories, make sure to subscribe to this YouTube channel by clicking the button above this video!
Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was "not true," without giving any more details.
Biogen said it does not comment on market rumors or speculation.
Its stock closed up 9.5% on Wednesday.
Any such deal would be the biggest overseas acquisition ever by a South Korean company.
The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.